YOUR SEARCH FOR Text 42 RESULTS
31 of Total
HCP Medical Resources & Support | Incyte.com
… . Patient Resources Explore Our Current Portfolio … HCP Medical Resources & Support | …
32 of Total
Global Biopharmaceutical Company | Incyte.com
… grown into a global organization with a robust portfolio of treatments across Oncology and …
33 of Total
Incyte to Report Third Quarter Financial Results | Incyte
… therapeutics, Incyte has established a portfolio of first-in-class medicines for …
34 of Total
Collaboration | Partners in Science | Incyte.com
… collaboration Explore Our Current Portfolio View Information for Investors … …
35 of Total
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Incyte
… therapeutics, Incyte has established a portfolio of first-in-class medicines for …
36 of Total
Serving Patients Through Innovation | Incyte Stories
… Incyte medicines, supporting both the Company’s portfolio as well as marketed products. Learn …
37 of Total
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the Eu
… therapeutics, Incyte has established a portfolio of first-in-class medicines for …
38 of Total
Dermatology Research: Immune-Mediated Dermatologic Conditions | Incyte.Com
… About Our Work in Oncology Explore Our Current Portfolio … Dermatology Research: …
39 of Total
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa | Incyt
… therapeutics, Incyte has established a portfolio of first-in-class medicines for …
40 of Total
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in
… therapeutics, Incyte has established a portfolio of first-in-class medicines for …